Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Forum Onward Medical geopend
Volgen
Dank je voor het plaatsen Voda. Weer een mooi p.b. Van Onward. Een redelijk onbekend beurs genoteerd bedrijf met, naar ik verwacht, een mooi vooruitzicht. Hetis te hopen voor de mensen met verlamming verschijnselen dat er nog meer positieve resultaten worden behaald in de nabije toekomst. Duimpje geplaatst;))
Allemaal mooie vooruitzichten en mooie woorden, maar toch blijft het aandeel zakken.
Ik heb sinds mijn vorige melding mijn positie weer iets uitgebreid naar 3275 stuks. Op deze niveau's blijf ik kleine aankopen doen. Komende maanden kunnen we waarde creërend nieuws verwachten volgens Marver. Buiten het feit dat de betere mobiliteit van personen met een dwarslaesie natuurlijk erg belangrijk is, mis ik wel een soort van waardeperspectief voor de toekomst. Stel dat deze behandelingen het maken wat zijn dan de potentiële opbrengsten?
At ONWARD, our team continues to work hard to develop therapies that can make a meaningful difference in the lives of people with spinal cord injury. Recent weeks have delivered the following achievements: Completion of enrollment in the LIFT Home Study We announced in early June that we had completed enrollment in the LIFT Home Study. This trial is designed to study the safety and performance of ARCEX Therapy when used in the home. The study enrolled 17 participants at five leading research centers in the US: Craig Hospital in Denver, Colorado, Shepherd Center in Atlanta, Georgia, Spaulding Research Institute in Boston, Massachusetts, University of Minnesota, and the University of Washington. Participants are followed for four weeks to assess whether continued access to ONWARD’s ARCEX Therapy is safe and can be used to enhance long-term benefit. The LIFT Home Study is a successor to ONWARD’s Up-LIFT Study, a pivotal trial that completed enrollment of 65 participants in December 2021, with participating research centers in the US, Canada, the UK, and Europe. Up-LIFT is designed to demonstrate ONWARD ARCEX Therapy can improve the strength and function of upper limbs when used in the rehabilitation clinic setting. Completing these studies is a major step toward the commercialization of ARCEX Therapy for restoration of hand and arm function as expected in 2023. You can learn more here. Release of “Onward with Scott Chesney” Interview with Erica Coulston As part of ONWARD’s continuing effort to engage with and learn from the SCI community, Scott Chesney released another in his interview series with leading SCI stakeholders. Erica Coulston, Co-Founder and President of Walk the Line shares her journey as a C6/7 quadriplegic and discusses her interest in potential therapies to restore blood pressure. As you may recall, ONWARD is working to develop, investigate, and potentially commercialize therapy to address orthostatic hypotension. Watch the interview and subscribe to the series on ONWARD’s YouTube channel. We expect several important developments later this summer and fall. I will be sure to keep you posted. Best wishes, Dave Dave Marver CEO
At ONWARD, our team continues to work hard to develop therapies that can make a meaningful difference in the lives of people with spinal cord injury. Recent weeks have delivered the following achievements: Completion of enrollment in the LIFT Home Study We announced in early June that we had completed enrollment in the LIFT Home Study. This trial is designed to study the safety and performance of ARCEX Therapy when used in the home. The study enrolled 17 participants at five leading research centers in the US: Craig Hospital in Denver, Colorado, Shepherd Center in Atlanta, Georgia, Spaulding Research Institute in Boston, Massachusetts, University of Minnesota, and the University of Washington. Participants are followed for four weeks to assess whether continued access to ONWARD’s ARCEX Therapy is safe and can be used to enhance long-term benefit. The LIFT Home Study is a successor to ONWARD’s Up-LIFT Study, a pivotal trial that completed enrollment of 65 participants in December 2021, with participating research centers in the US, Canada, the UK, and Europe. Up-LIFT is designed to demonstrate ONWARD ARCEX Therapy can improve the strength and function of upper limbs when used in the rehabilitation clinic setting. Completing these studies is a major step toward the commercialization of ARCEX Therapy for restoration of hand and arm function as expected in 2023. You can learn more here. Release of “Onward with Scott Chesney” Interview with Erica Coulston As part of ONWARD’s continuing effort to engage with and learn from the SCI community, Scott Chesney released another in his interview series with leading SCI stakeholders. Erica Coulston, Co-Founder and President of Walk the Line shares her journey as a C6/7 quadriplegic and discusses her interest in potential therapies to restore blood pressure. As you may recall, ONWARD is working to develop, investigate, and potentially commercialize therapy to address orthostatic hypotension. Watch the interview and subscribe to the series on ONWARD’s YouTube channel. We expect several important developments later this summer and fall. I will be sure to keep you posted. Release of “Onward with Scott Chesney” Interview with Erica Coulston As part of ONWARD’s continuing effort to engage with and learn from the SCI community, Scott Chesney released another in his interview series with leading SCI stakeholders. Erica Coulston, Co-Founder and President of Walk the Line shares her journey as a C6/7 quadriplegic and discusses her interest in potential therapies to restore blood pressure. As you may recall, ONWARD is working to develop, investigate, and potentially commercialize therapy to address orthostatic hypotension. Watch the interview and subscribe to the series on ONWARD’s YouTube channel. We expect several important developments later this summer and fall. I will be sure to keep you posted. Best wishes, Dave Dave Marver CEO Best wishes, Dave Dave Marver CEO
Een nieuwe positieve update zou mooi zijn. Of was dit al het nieuws dat we mochten verwachten deze zomer? Ik geloof echt in dit aandeel omwille van de reeds bewezen resultaten, maar begin er toch aan te twijfelen of het al uitgebodemd is. Hebben die investeerders aan IPO prijs aangekocht?
Dark_enRahl schreef op 7 augustus 2022 21:19 :
Een nieuwe positieve update zou mooi zijn. Of was dit al het nieuws dat we mochten verwachten deze zomer? Ik geloof echt in dit aandeel omwille van de reeds bewezen resultaten, maar begin er toch aan te twijfelen of het al uitgebodemd is. Hebben die investeerders aan IPO prijs aangekocht?
Het is inderdaad al een tijdje stil. Volgens de CEO zouden er nog enkele nieuwsberichten naar buiten komen in de periode juli t/m december 2022. Een update over lopende onderzoeken bijvoorbeeld. Vwb de investeerders ga ik er vanuit dat ze niet veel lager ingestapt zijn dan de huidige beurskoers. Vanaf het hoogtepunt is er al 8 euro verdwenen, meer dan een halvering. De cijfers over kwartaal 2 zullen binnenkort ook wel verschijnen?
Hieronder een stukje uit de laatste nieuwsbrief van Onward Medical As you may recall, ONWARD is working to develop, investigate, and potentially commercialize therapy to address orthostatic hypotension. Watch the interview and subscribe to the series on ONWARD’s YouTube channel. We expect several important developments later this summer and fall. I will be sure to keep you posted. Best wishes, Dave Dave Marver CEO Verder komen de half jaar cijfers op 27 September.
Die 10775 stuks order op 4,80 moet en zal geleverd worden gok ik. @renno, Ik vermoed ook dat we nog een reeks aan berichten voorbij zullen zien komen vanuit Onward de komende maanden.
In de tussentijd mijn positie weer licht uitgebreid naar 3750 stuks voor een in mijn ogen mooie prijs.
Competing with other innovative Swiss SMEs, ONWARD has won a Sino-Swiss Business Incubation award in the HealthTech category. Winners of this #SSBI program receive resources and financial support to establish partnerships and determine market-entry strategies for China. We thank SSBICom, Swiss-Chinese Chamber of Commerce (SCCC), and Innovaud for their support.
Mooi! Wederom een award. Het is wel uniek dat deze en de vorige award door forumleden gevonden en geplaatst zijn. Vanuit IEX of diverse brokers geen enkel bericht daarover.
Ik moet zeggen, ik wacht de halfjaarcijfers even af, dan kijk ik of ik instap. Wat een slechte website heeft die tent!!
ONWARD Announces Participation at Upcoming Investor Events in September EINDHOVEN, the Netherlands & LAUSANNE, Switzerland—September 7, 2022--ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today announced that management will participate in the following upcoming investor events in September: • KBC Securities Virtual Life Sciences Conference September 16, 2022 Dave Marver, CEO, and Lara Smith Weber, CFO, will participate in the conference and give a company presentation. • btov Portfolio Day September 21, 2022 Berlin, Germany Lara Smith Weber, CFO, will give a company presentation. Information on upcoming conferences is available in the investor section of the ONWARD website at ir.onwd.com/news-events.
About ONWARD Medical ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the U.S. FDA, encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non- invasive platform consisting of a wearable stimulator and wireless programmer. The company’s first pivotal trial, called Up-LIFT, evaluating the ability of ARCEX Therapy to improve upper extremity strength and function, completed enrollment in December 2021 with 65 subjects worldwide. Topline results are expected in September 2022. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022
De laat word flink aangevallen. Mooie herstelbeweging op een bovengemiddeld volume. Hebben we het keerpunt bereikt?
Laten we het hopen?? ook dat de topline results voor ARCEX in september goed zullen zijn ( ik verwacht van wel )
Hopen?? Moet zijn hopen!!
Mooie start van de week. Hopelijk kunnen we de 4 euro achter ons laten en de hogere regionen opzoeken tot aan de cijfers en updates.
Positieve studieresultaten Onward Lancering in tweede helft 2023. (ABM FN-Dow Jones) Onward Medical heeft positieve resultaten geboekt met een studie naar het herstellen van de arm- en handfunctie van mensen die lijden aan ruggengraatletstel. Dit maakte het bedrijf dinsdagochtend bekend. Het primaire eindpunt op het vlak van effectiviteit werd met de studie behaald. "Het herstellen van de hand- en armfunctie na een dwarslaesie is levensveranderend", aldus Onward. Inmiddels is Onward druk bezig met het voorbereiden van de aanvragen bij de toezichthouders en de lancering in de VS en Europa. CEO Dave Marver denkt dat dit in de tweede helft van 2023 zou moeten lukken. Door: ABM Financial News.info@abmfn.nl Redactie: +31(0)20 26 28 999
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee